摘要
Fulminant hepatitis is a serious and complex disease with high mortality. In recent years, hepatocyte growth-promoting factors (pHGF), developed on the basis of fetal liver cell injection, has been jointly used as a comprehensive therapy for fulminant hepatitis. The following is a report of the results of using pHGF for the treatment of 1687 cases of fulminant hepatitis (with 1196 controls).
